Anna Sureda performs multidisciplinary study on Internal medicine and Family medicine in her works. Family medicine and Internal medicine are two areas of study in which she engages in interdisciplinary work. She conducts interdisciplinary study in the fields of Lymphoma and CD20 through her works. Anna Sureda merges CD20 with Lymphoma in her study. Anna Sureda integrates several fields in her works, including Oncology and Gastroenterology. She carries out multidisciplinary research, doing studies in Gastroenterology and Oncology. Her research on Refractory (planetary science) frequently links to adjacent areas such as Astrobiology. Astrobiology and Refractory (planetary science) are commonly linked in her work. Anna Sureda combines Multidisciplinary approach and Social science in her studies.
Daratumumab, Carfilzomib and Pomalidomide are the main topics of her Lenalidomide study. As part of her studies on Daratumumab, Anna Sureda frequently links adjacent subjects like Bortezomib. In her papers, Anna Sureda integrates diverse fields, such as Bortezomib and Thalidomide. In her works, Anna Sureda undertakes multidisciplinary study on Thalidomide and Lenalidomide. As part of her studies on Pomalidomide, Anna Sureda often connects relevant areas like Multiple myeloma. She performs multidisciplinary study in Multiple myeloma and Carfilzomib in her work. Anna Sureda integrates Internal medicine with Family medicine in her research. Anna Sureda brings together Family medicine and Internal medicine to produce work in her papers. Oncology and Gastroenterology are two areas of study in which Anna Sureda engages in interdisciplinary research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz;Auayporn Nademanee;Tamas Masszi;Edward Agura.
The Lancet (2015)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Bruno Paiva;Maria-Belén Vidriales;Jorge Cerveró;Gema Mateo.
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.
P. Ljungman;M. Bregni;M. Brune;J. Cornelissen.
Bone Marrow Transplantation (1998)
Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
Jakob Passweg;H. Baldomero;P. Bader;Chiara Bonini.
Bone Marrow Transplantation (2016)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge.
The Lancet (2019)
Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Anna Sureda;Stephen Robinson;Carmen Canals;Angelo M. Carella.
Journal of Clinical Oncology (2008)
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Alois Gratwohl;Martin Stern;Ronald Brand;Jane Apperley.
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan José Lahuerta;Maria Victoria Mateos;Joaquin Martínez-López;Laura Rosiñol.
Journal of Clinical Oncology (2008)
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
A. Sureda;P. Bader;S. Cesaro;P. Dreger.
Bone Marrow Transplantation (2015)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva;Norma C. Gutiérrez;Laura Rosiñol;María-Belén Vídriales.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: